Breast Cancer Patient Discussion Guide
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Breast Cancer Patient Brochure
Read More
-
Signatera CRC Brochure
Read More
-
Signatera IO One Sheet
Read More
-
Circulate Japan Sales Aid
Read More
-
Oncology Pan Portfolio
Read More
-
Signatera Melanoma Data Sheet
Read More
-
Signatera Pan Tumor Guide
Read More
-
SABCS 2022 Product Theater Section 1 - The Cycle of ctDNA in Breast Cancer
Watch Video
-
SABCS 2022 Product Theater
Watch Video
-
SABCS 2022 Product Theater Section 5 - Limitations and Eblis
Clinical Applications for Signatera in Breast Cancer Surveillance
Watch Video
-
SABCS 2022 Product Theater Section 4 - Example Case
Real World Case Study: Personalized ctDNA Testing for High Risk Breast Cancer Surveillance
Watch Video
-
SABCS 2022 Product Theater Section 3 - ctDNA Utility
Clinical utility of personalized ctDNA testing in breast cancer treatment
Watch Video
-
SABCS 2022 Product Theater Section 2 - MRD
Clinical applications of ctDNA testing for MRD assessment in breast cancer
Watch Video
-
New ctDNA GU cancers data: improve patient management in bladder and kidney
Watch Video
-
Monitoring ctDNA in Breast Cancer: Moving on with life with Signatera
Watch Video
-
Optimize breast cancer management: Incorporating personalized ctDNA testing into your practice
Watch Video
-
Know Cancer’s Next Move: Using ctDNA to guide treatment decisions in patients with GI Cancer
Watch Video
-
Signatera ICD-10 Codes
Read Article
-
A multicenter, prospective observational study to evaluate the impact of circulating tumor DNA guided therapy on patients with colorectal ca
Read More
-
Loading More...
